Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Cosentyx

13 posts
NNovartis
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Read More

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

  • 2026-06-11
Novartis Pharma AG Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid…
NNovartis
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Read More

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

  • 2026-06-09
Novartis Pharma AG Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid…
NNovartis
VOH Logo
Read More

Novartis Presents 31 Immunology Abstracts at EULAR 2026

  • 2026-06-06
Novartis will present new data from 31 abstracts across its immunology portfolio at the European Alliance of Associations…
NNovartis
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica
Read More

Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica

  • 2026-06-05
Novartis AG (NYSE:NVS) is one of the best cheap stocks to buy for beginners. Novartis AG (NYSE:NVS) announced on…
NNovartis
Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus
Read More

Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus

  • 2026-06-04
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
NNovartis
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Read More

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

  • 2026-06-03
Novartis Pharma AG Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid…
NNovartis
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Read More

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

  • 2026-06-03
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent…
NNovartis
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Read More

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

  • 2026-06-03
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
NNovartis
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Read More

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

  • 2026-03-23
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
NNovartis
Yahoo news home
Read More

Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

  • 2026-03-16
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients…
NNovartis
Yahoo news home
Read More

Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

  • 2026-03-16
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients…
NNovartis
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Read More

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

  • 2026-03-15
Novartis Pharma AG Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism…
Switzerland
www.europesays.com